News room

Egetis is an innovative, unique, and integrated pharmaceutical drug development company, focusing on projects in late-stage development for treatment of serious rare/niche diseases with significant unmet medical needs in the orphan drug segment

Egetis Therapeutics appoints Yilmaz Mahshid as new CFO

April 19, 2021

Stockholm, Sweden, April 19, 2021. Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that Yilmaz Mahshid, PhD, has been appointed Chief Financial Officer (CFO), joining in the second quarter of 2021. He will be part of the company’s management team and report to the CEO.

Yilmaz has experience from different senior positions in the life science sector, including Investment Manager & Controller at Industrifonden, and CFO at PledPharma between 2017 and 2020, as well as healthcare analyst at Pareto Securities and Öhman Fondkommission. Prior to joining Egetis Therapeutics, Yilmaz was CEO of the listed biotech company Medivir.
 
Yilmaz also has a solid academic background with a PhD from the Department of Medical Biochemistry and Biophysics at Karolinska Institutet, Stockholm.
 
He is taking over from Marie-Louise Alamaa, who joined as interim CFO in June 2020.
 
"We are pleased to welcome Yilmaz to Egetis. His extensive experience and knowledge in financial management, business development, investor relations and medical science makes him ideal in the role of CFO at Egetis, and I look forward to work with Yilmaz again. I also want to take this opportunity to thank Marie-Louise for her hard and diligent work as an interim CFO. Her drive, experience and significant knowledge within the field of finance was instrumental during the integration of Rare Thyroid Therapeutics (RTT) and the formation of Egetis", said Nicklas Westerholm, CEO of Egetis Therapeutics.
 
"It is going to be great to work with Nicklas and his team again and contribute to Egetis continued work to create value for its shareholders and all the patients who could benefit from the company's late-stage portfolio of innovative orphan drug candidates in rare diseases," said Yilmaz Mahshid.

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com